For research use only. Not for therapeutic Use.
Milataxel is an orally bioavailable taxane with potential antineoplastic activity. Upon oral administration, milataxel and its major active metabolite M-10 bind to and stabilize tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, milataxel appears to be a poor substrate for the multidrug resistance (MDR) membrane-associated P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
| Catalog Number | R025415 |
| CAS Number | 393101-41-2 |
| Synonyms | (αR,βR)β-[[(1,1-Dimethylethoxy)carbonyl]amino]-α-hydroxy-2-furanpropanoic acid, (2aR,4S,4aS,6R,9S,11S,12S,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-4-(1-oxopropoxy) |
| Molecular Formula | C₄₄H₅₅NO₁₆ |
| Purity | ≥95% |
| Target | tublin inhibitor |
| Storage | -20°C |
| Reference | </br>1:Overcoming extractability hurdles of a 14C labeled taxane analogue milataxel and its metabolite from xenograft mouse tumor and brain tissues. Safarpour H, Connolly P, Tong X, Bielawski M, Wilcox E.J Pharm Biomed Anal. 2009 Apr 5;49(3):774-9. doi: 10.1016/j.jpba.2008.12.034. Epub 2008 Dec 31. PMID: 19186016 </br>2:A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer. Ramanathan RK, Picus J, Raftopoulos H, Bernard S, Lockhart AC, Frenette G, Macdonald J, Melin S, Berg D, Brescia F, Hochster H, Cohn A.Cancer Chemother Pharmacol. 2008 Mar;61(3):453-8. Epub 2007 May 22. PMID: 17516069 |
